IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1001-1025 out of 1246.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

Public Release: 2-Jun-2014
ASCO 50th Annual Meeting
New data shows ProMark accurately predicts aggressive prostate cancer, pathology outcomes
Metamark presents data showing test accurately predicts low/high risk prostate cancer.

Contact: Theresa Dolge
Theresa.Dolge@toniclc.com
215-928-2748
Tonic Life Communications USA

Public Release: 2-Jun-2014
Journal of Clinical Oncology
Expanded health coverage may improve cancer outcomes in young adults, study suggests
Young adults who lack health care insurance are more likely to be diagnosed in advanced stages of cancer and have a higher risk of death, according to a study from Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.
Heritage Medical Research Institute

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 2-Jun-2014
ASCO 50th Annual Meeting
Study shows tale of 2 prognoses in pediatric brain tumor, pilocytic astrocytoma
Research presented at the American Society for Clinical Oncology Annual Meeting 2014 used a newly designed test for K:B fusion to show that point mutations lead to a more dangerous form of the disease than does K:B fusion.
NIH/National Cancer Institute

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

Public Release: 2-Jun-2014
Annals of Internal Medicine
News from Annals of Internal Medicine tip sheet June 3, 2014
The June 3, 2014, issue of Annal of Internal Medicine contains the following papers: 'For some, screening for colorectal cancer should continue well past age 75,' 'Practices using patient-centered medical home with EHRs have improved quality of care,' and 'Observation: Tanning beds associated with vitamin D toxicity?'

Contact: Megan Hanks
mhanks@acponline.org
215-351-2656
American College of Physicians

Public Release: 2-Jun-2014
ASCO 50th Annual Meeting
Myriad presents clinical data on Myriad myRisk Hereditary Cancer Test at ASCO
Data being presented at the 2014 American Society of Clinical Oncology meeting show that the Myriad myRisk Hereditary Cancer test detects significantly more deleterious mutations than single cancer tests and helps solve the overlap dilemma that exists among hereditary cancer syndromes. The myRisk test uses next-generation sequencing technology to evaluate 25 clinically significant hereditary cancer genes associated with eight major hereditary cancers including: breast, colon, ovarian, endometrial, pancreatic, prostate, gastric cancers and melanoma.

Contact: Ronald Rogers
rrogers@myriad.com
908-285-0248
Myriad Genetics, Inc.

Public Release: 2-Jun-2014
ASCO 50th Annual Meeting
Myriad myPath melanoma test improves the reliability of melanoma diagnosis
Results from a pivotal clinical validation study of the Myriad myPath Melanoma test at the 2014 American Society of Clinical Oncology meeting show that it accurately differentiates malignant melanoma from benign skin lesions with a high level of accuracy and helps physicians deliver a more objective and confident diagnosis for patients. The Myriad myPath Melanoma test is a unique test of 23 genes that provides valuable, additive diagnostic information unavailable from any other method.

Contact: Ronald Rogers
rrogers@myriad.com
908-285-0248
Myriad Genetics, Inc.

Public Release: 1-Jun-2014
Nature Genetics
Smokers with gene defect have 1 in 4 chance of developing lung cancer
Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals.

Contact: Henry French
henry.french@icr.ac.uk
020-715-35582
Institute of Cancer Research

Public Release: 1-Jun-2014
Nature Genetics
Newly identified brain cancer mutation will aid drug development
A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma.
NIH/National Cancer Institute

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 1-Jun-2014
ASCO 50th Annual Meeting
Oncologists: How to talk with your pathologist about cancer molecular testing
Aisner suggests close communication, systems approaches, keeping special requests to a minimum, and patience on the part of requesting oncologists. The key, she says, is writing new institutional protocols to keep pace with the new reliance on molecular testing.

Contact: Erika Matich
erika.matich@ucdenver.edu
University of Colorado Denver

Public Release: 1-Jun-2014
Nature Medicine
'Quadrapeutics' works in preclinical study of hard-to-treat tumors
A Rice University-led study in this week's Nature Medicine reports the first preclinical tests for a novel anti-cancer technology called 'quadrapeutics' that converts current clinical treatments to instantaneously detect and kill only cancer cells. Quadrapeutics combines clinically available drugs, colloidal gold, pulsed lasers and radiation in a novel and safe micro-treatment that improved standard therapy by 17-fold against aggressive, drug-resistant tumors.
National Institutes of Health, National Science Foundation, Simmons Family Foundation

Contact: Jade Boyd
jadeboyd@rice.edu
713-348-6778
Rice University

Public Release: 1-Jun-2014
CA: A Cancer Journal for Clinicians
New report estimates nearly 19 million cancer survivors in the US by 2024
The number of cancer survivors in the United States, currently estimated to be 14.5 million, will grow to almost 19 million by 2024.
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 1-Jun-2014
ASCO 50th Annual Meeting
Journal of Clinical Oncology
Chemotherapy following radiation treatment improves progression-free survival
A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the 2014 American Society of Clinical Oncology Annual Meeting by the study's primary author Jan Buckner, M.D., deputy director, Cancer Practice, at Mayo Clinic Cancer Center.
National Cancer Institute

Contact: Joe Dangor
507-284-5005
Mayo Clinic

Public Release: 1-Jun-2014
Nature
Paired enzyme action in yeast reveals backup system for DNA repair
The combined action of two enzymes, Srs2 and Exo1, prevents and repairs common genetic mutations in growing yeast cells, according to a new study led by scientists at NYU Langone Medical Center.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 1-Jun-2014
ASCO 50th Annual Meeting
New England Journal of Medicine
Prostate cancer drug delivers benefits before chemotherapy
A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University.
Medivation, Astellas Pharma

Contact: Elisa Williams
willieli@ohsu.edu
971-344-5441
Oregon Health & Science University

Public Release: 1-Jun-2014
ASCO 50th Annual Meeting
Major advances in breast, prostate, colorectal cancer featured at ASCO Annual Meeting
Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology. The studies were presented in ASCO's Plenary session, which features the meeting's most important clinical cancer research with the greatest potential to impact patient care.

Contact: Wendy Stokes
wendy.stokes@asco.org
312-949-3232
American Society of Clinical Oncology

Public Release: 1-Jun-2014
ASCO 50th Annual Meeting
Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting.
2014 American Society of Clinical Oncology Annual Meeting

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 1-Jun-2014
ASCO 50th Annual Meeting
Drug combination extends survival by more than a year in metastatic prostate cancer
Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.
NIH/National Cancer Institute, National Institutes of Health

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
440-670-6563
Dana-Farber Cancer Institute

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
At the 50th Annual Meeting of the American Society for Clinical Oncology, University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28, an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells. The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months.

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease
A study presented at the American Society of Clinical Oncology Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Patients with metastatic colon cancer respond to new combination therapy
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.

Contact: William Fitzgerald
externalcomm@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Immune therapy for advanced bladder cancer yields promising results
A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology in Chicago.

Contact: Vicky Agnew
vicky.agnew@yale.edu
843-697-6208
Yale University

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Studies reveal potential new targeted therapies for common, hard-to-treat cancers
Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology. Findings from the mid- and late-stage trials suggest new ways to slow disease progression and improve survival for patients who experience relapses or resistance to available treatments.

Contact: Kelly Baldwin
kelly.baldwin@asco.org
312-949-3232
American Society of Clinical Oncology

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Clinical trial shows drug combination may be highly effective in recurrent ovarian cancer
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago today.
National Institutes of Health

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
440-670-6563
Dana-Farber Cancer Institute

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Studies reveal new strategies to improve quality of life
Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology identify new strategies for easing the short- and long-term effects of cancer therapy and improving the quality of life of patients with cancer, as well as their caregivers.

Contact: Kelly Baldwin
kelly.baldwin@asco.org
312-949-3232
American Society of Clinical Oncology

Public Release: 31-May-2014
ASCO 50th Annual Meeting
Clinical trial shows drug combination may be effective in recurrent ovarian cancer
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago today. This is the first ovarian cancer study to use a combination of drugs that could be taken orally.
NIH/National Cancer Institute

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
440-670-6563
Dana-Farber Cancer Institute

Showing releases 1001-1025 out of 1246.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

  Search News Releases

     

 

EurekAlert!